Share Email Print

Journal of Biomedical Optics

Quantum dots targeted to vascular endothelial growth factor receptor 2 as a contrast agent for the detection of colorectal cancer
Format Member Price Non-Member Price
PDF $20.00 $25.00

Paper Abstract

We successfully labeled colorectal cancer in vivo using quantum dots targeted to vascular endothelial growth factor receptor 2 (VEGFR2). Quantum dots with emission centered at 655 nm were bioconjugated to anti-VEGFR2 antibodies through streptavidin/biotin linking. The resulting QD655-VEGFR2 contrast agent was applied in vivo to the colon of azoxymethane (AOM) treated mice via lavage and allowed to incubate. The colons were then excised, cut longitudinally, opened to expose the lumen, and imaged en face using a fluorescence stereoscope. The QD655-VEGFR2 contrast agent produced a significant increase in contrast between diseased and undiseased tissues, allowing for fluorescence-based visualization of the diseased areas of the colon. Specificity was assessed by observing insignificant contrast increase when labeling colons of AOM-treated mice with quantum dots bioconjugated to isotype control antibodies, and by labeling the colons of saline-treated control mice. This contrast agent has a great potential for in vivo imaging of the colon through endoscopy.

Paper Details

Date Published: 6 August 2014
PDF: 8 pages
J. Biomed. Opt. 19(8) 086003 doi: 10.1117/1.JBO.19.8.086003
Published in: Journal of Biomedical Optics Volume 19, Issue 8
Show Author Affiliations
Jordan L. Carbary-Ganz, The Univ. of Arizona (United States)
Jennifer K. Barton, The Univ. of Arizona (United States)
Urs Utzinger, The Univ. of Arizona (United States)

© SPIE. Terms of Use
Back to Top